Colinz Laboratories

Colinz Laboratories Debt/EBITDA

The Total Debt to EBITDA Ratio of Colinz Laboratories (531210.BO) as of Nov 3, 2026 is 1.29. In the previous year, Total Debt to EBITDA Ratio was 1.03 — a change of 25.18% (higher).

Debt/EBITDA

1.29

YoY

25.18%

Last updated:

Total Debt to EBITDA Ratio of Colinz Laboratories is 2025 1.29 . Total Debt to EBITDA Ratio of Colinz Laboratories was 2024 1.03 . It decreases by 25.18% higher compared to the previous year.

The Colinz Laboratories Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
1.17 INR
Jan 1, 2019
1.93 INR
Jan 1, 2020
1.26 INR
Jan 1, 2021
2.99 INR
Jan 1, 2022
0.83 INR
Jan 1, 2023
0.43 INR
Jan 1, 2024
1.03 INR
Jan 1, 2025
1.29 INR
The Colinz Laboratories Debt/EBITDA history
YEARDebt/EBITDAYoY
1.29+25.18%
1.03+139.28%
0.43-47.72%
0.83-72.36%
2.99+137.88%
1.26-34.73%
1.93+64.28%
1.17-36.80%
1.86-65.07%
5.31-48.22%
10.26+9.60%
9.36—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Colinz Laboratories Stock analysis

What does Colinz Laboratories do? Colinz Laboratories Ltd manufactures pharmaceutical formulations including tablets, capsules, granules, liquid orals, injectables, ointments, and creams. The company markets allopathic and ayurvedic products targeting hypertension, cholesterol, diabetes, piles, pyrexia, and malaria treatments for physicians. Gynecologists receive specialized products for morning sickness, infertility, IUGR, and pregnancy maintenance. Additional offerings include hematinic, antispasmodic, anti-inflammatory/anti-allergic tablets, capsules, gel, and medicated shampoo. Products are sold across Maharashtra, Karnataka, Andhra Pradesh, Gujarat, Rajasthan, Madhya Pradesh, Chhattisgarh, and West Bengal through the company's own marketing team. The firm's revenue streams come from direct sales to healthcare professionals and pharmacies within its operational states. Physicians prescribe products for chronic conditions like hypertension and diabetes, while gynecologists utilize specialized treatments for pregnancy-related issues. The company's product portfolio spans both conventional allopathic medicines and traditional ayurvedic formulations, catering to diverse medical needs. Marketing efforts focus on state-specific distribution through dedicated in-house sales staff. Colinz Laboratories Ltd serves the pharmaceutical market segment with a clear focus on regional healthcare providers. Its product range addresses common health concerns such as cardiovascular issues, metabolic disorders, and pregnancy care. The company's strategy involves direct engagement with medical practitioners to promote its formulations, ensuring consistent market presence in key Indian states without external partnerships or third-party distribution channels. Colinz Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Colinz Laboratories stock

Total Debt to EBITDA Ratio of Colinz Laboratories is 1.29 in 2025.

Total Debt to EBITDA Ratio of Colinz Laboratories changed from 1.03 to 1.29, representing a 25.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Colinz Laboratories since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Colinz Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Colinz Laboratories

All Key Metrics — Colinz Laboratories